Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7810578 | 0.95 | CHRM2 (0.64) | CHRM2CHRM1 | |
| Fumaric Acid SCHEMBL7820915 | 0.92 | CHRM2 (0.51) | CHRM2CHRM1 | |
| Oxalic Acid SCHEMBL7819179 | 0.91 | CHRM2 (0.58) | CHRM2CHRM1 | |
| SCHEMBL7810907 | 0.89 | CHRM2 (0.65) | CHRM2CHRM1 | |
| SCHEMBL8195856 | 0.85 | CHRM1 (0.54) | CHRM1 | |
| Oxalic Acid SCHEMBL7811971 | 0.85 | CHRM2 (0.61) | CHRM2CHRM1 | |
| SCHEMBL8202813 | 0.84 | CHRM2 (0.57) | CHRM2 | |
| Hydrochloric Acid SCHEMBL8200001 | 0.84 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL7818023 | 0.84 | CHRM2 (0.48) | CHRM2 | |
| SCHEMBL8188383 | 0.81 | CHRM2 (0.59) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6281233-B1 | AZABICYCLIC RING-SUBSTITUTED THIA- OR OXADIAZOLES | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | claimed |
| EP-0714394-B1 | ANTIPSYCHOTIC METHOD WITH THIADIAZOLE AND OXADIAZOLE DERIVATIVES | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | EP | claimed |
| EP-0544779-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1998-12-02 | — | — | EP | claimed |
| EP-0873124-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1998-10-28 | — | — | EP | claimed |
| EP-0866702-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-09-30 | — | — | EP | claimed |
| WO-1997020556-A9 | METHOD FOR TREATING PAIN | — | 1997-10-02 | — | — | WO | claimed |
| WO-1997025043-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1997-07-17 | — | — | WO | claimed |
| WO-1997020556-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| EP-0714394-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-06-05 | — | — | EP | claimed |
| WO-1996014316-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | claimed |
| WO-1995005379-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | claimed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-0873124-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997025043-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1997-07-17 | — | — | WO | disclosed |
| WO-1996013166-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0709093-A2 | Method for treating anxiety using an azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5484794-A | THIA- OR OXA-DIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | CHRM2 3365/4885CHRM1 3495/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | CHRM2 3568/4885CHRM1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.